Get started
Author

Leonid Shunyakov

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
2023 · H. Borghaei, F. de Marinis, et al. · Annals of Oncology · 103
PDF
A practical approach to aid physician interpretation of clinically actionable predictive biomarker results in a multi-platform tumor profiling service
2014 · Kenneth Russell, Leonid Shunyakov, et al. · Frontiers in Pharmacology · 10
PDF
P1.13A.10 Efficacy and Safety of Lurbinectedin for Small Cell Lung Cancer in a Real-World Setting: Jazz EMERGE 402 Study
2024 · B. Halmos, P. Lammers, et al. · Journal of Thoracic Oncology · 2
PDF
Real-world safety and healthcare resource utilization (HCRU) of lurbinectedin (lurbi) in patients (pts) with small cell lung cancer (SCLC): Jazz EMERGE 402 updated analysis.
2024 · Firas Benyamine Badin, Philip Edward Lammers, et al. · Journal of Clinical Oncology · 1
PDF
P2.17-07 Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis
2023 · B. Halmos, P. Lammers, et al. · Journal of Thoracic Oncology · 1
PDF
Real-world (RW) effectiveness and safety of lurbinectedin (lurbi) for previously treated extensive-stage small cell lung cancer (ES-SCLC): Final primary and subgroup analysis results of Jazz EMERGE 402.
2026 · Firas Benyamine Badin, Phil Lammers, et al. · Journal of Clinical Oncology
PP01.138: Real-World Effectiveness and Safety of Lurbinectedin for Small Cell Lung Cancer (SCLC): Updates From Jazz EMERGE 402
2026 · Firas Badin, Philip Lammers, et al. · Journal of Thoracic Oncology
429P Real-world (RW) effectiveness and safety of lurbinectedin for previously treated small cell lung cancer (SCLC): Jazz EMERGE 402
2026 · B. Halmos, P. Lammers, et al. · ESMO Open
PDF
Place in therapy of key treatments for platinum-sensitive, relapsed, extensive-stage small cell lung cancer with a focus on lurbinectedin: a narrative review with case studies
2025 · Leonid Shunyakov, Firas B Badin, et al. · Drugs in Context
PDF
P3.13.31 Real-World Effectiveness and Safety of Lurbinectedin for Small Cell Lung Cancer (SCLC): Updates From Jazz EMERGE 402
2025 · B. Halmos, P. Lammers, et al. · Journal of Thoracic Oncology
OA08.04 Plinabulin/Docetaxel vs. Docetaxel in 2L/3L NSCLC after Platinum Regimens (DUBLIN-3): A Phase 3 Randomized Controlled Trial
2024 · T. Feinstein, B. Han, et al. · Journal of Thoracic Oncology
PDF
PP01.119 Real-World Use of Lurbinectedin in Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis
2024 · Balazs Halmos, Philip Lammers, et al. · Journal of Thoracic Oncology
PDF
P2.07-06 Real World Efficacy of First-Line Immunotherapy +/- Chemotherapy in Advanced NSCLC Stratified by Serum Proteomics
2023 · W. Akerley, H. Halawani, et al. · Journal of Thoracic Oncology
PDF
P1109: Trial in Progress: Phase 1b/2 Trial of Tazemetostat in Combination With Various Treatments in Patients With Relapsed or Refractory Hematologic Malignancies
2022 · A. Bessudo, D. Greenwald, et al. · HemaSphere
P60.10 Tumor Neoantigen Burden and Immune Environment in Driver Alteration-Positive Lung Adenocarcinoma.
2021 · B. Leibowitz, L. Kujtan, et al. · Journal of Thoracic Oncology
PDF
Works count: 15
Citation count: 117
H-index: 2
I10-index: 2
Year
Topic
Type